Explore the words cloud of the IgEPath project. It provides you a very rough idea of what is the project "IgEPath" about.
The following table provides information about the project.
MEDIZINISCHE UNIVERSITAET WIEN
|Coordinator Country||Austria [AT]|
|Total cost||166˙156 €|
|EC max contribution||166˙156 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2015-08-03 to 2017-08-02|
Take a look of project's partnership.
|1||MEDIZINISCHE UNIVERSITAET WIEN||AT (WIEN)||coordinator||166˙156.00|
In combination, Immunoglobulin E antibodies (IgEs) and IgE effector cells, most importantly mast cells (MCs) and basophils, are best known for their disease-causing roles in allergic conditions. MCs can also participate in innate host defense against pathogens and toxins. In contrast, physiologic functions of IgEs that benefit the host are still elusive. Dr. Philipp Starkl led a recent study reporting the critical role of IgEs and IgE effector cells in a beneficial type 2 immune response against bee venom in mice, supporting the idea that allergies represent defense mechanisms against toxins. Toxins that induce IgE development are also produced by various pathogenic bacteria. IgE production during bacterial infection has been considered detrimental since it is associated with the exacerbation of atopic diseases. This study investigates the hypothesis that toxin-specific IgEs can be important for acquired immunity against pathogenic bacteria by increasing the sensitivity, extent and specificity of the bactericidal MC response. The main objective of this study is to decipher the roles of IgEs and IgE effector cells in host defense against invasive secondary infections with antibiotic resistant pathogenic bacteria, which are a major health problem in Europe. The experimental approach facilitates knowledge transfer between the US and EU and complementarily combines the applicant’s expertise in type 2 immunity, IgEs and MCs (acquired in the US) and Prof. Sylvia Knapp’s competence in bacterial infections and involves in vivo mouse models of infection in transgenic mouse strains and MC in vitro models. The secondment in a pharmaceutical company will inspire collaboration and translation of results into vaccine development. This MSC fellowship will support the applicant’s career development by fostering acquisition of novel expertise in infectious diseases, collaboration with and reintegration into the European research community and connecting with the industrial sector.
|year||authors and title||journal||last update|
Kaori Mukai, Mindy Tsai, Philipp Starkl, Thomas Marichal, Stephen J. Galli
IgE and mast cells in host defense against parasites and venoms
published pages: 581-603, ISSN: 1863-2297, DOI: 10.1007/s00281-016-0565-1
|Seminars in Immunopathology 38/5||2019-06-13|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IGEPATH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IGEPATH" are provided by the European Opendata Portal: CORDIS opendata.
Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and IconographyRead More
A multilinear approach to the restriction problem with applications to geometric measure theory, the Schrödinger equation and inverse problemsRead More
Natural Product-Inspired Therapies for Leishmaniasis and Chagas DiseaseRead More